- Posted Wednesday September 10, 2014
TGen and Dell provide critical tools for child-cancer research to National Cancer Institute
Dell Genomic Data Analysis Platform provides computational power needed to speed up development of personalized treatment options
PHOENIX, Ariz. - Sept. 10, 2014 - Dell, Terascala and the Translational Genomics Research Institute (TGen) are installing state-of-the-art computing and programing specialized for human genome investigations at the National Cancer Institute (NCI).
As part of a formal collaboration, Dell is providing the Dell
Genomic Data Analysis Platform, designed to deliver fast analysis
of the billions of data points required when sequencing, or
decoding, aspects of the human DNA and other genomic data.
TGen is providing NCI with high performance computing and bioinformatics support, as well as specialized software and tools developed over the last three years as TGen and Dell have partnered in support of pediatric cancer research programs globally, including a groundbreaking personalized medicine trial for pediatric cancer conducted by the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC).
NCI is providing TGen with access to more than 800 sequenced child-cancer genomes, which will be used in TGen's ongoing pediatric cancer research.
"This is an enormous opportunity for the government to work with top private and research organizations to share information and expertise that will help guide physicians and medical benefit for children around the world. A system like this is critical in expediting patient care," said James Lowey, TGen's Vice President of Technology.
The mission of the Oncogenomics Section at the NCI is to harness the power of high throughput genomic and proteomic methods to improve the outcome of children with high-risk metastatic, refractory and recurrent cancers.
The new system at NCI will be used for four purposes:
1. House genomics data of well over 800 pediatric cancers, in a user friendly database.
2. RNAseq and immunohistochemistry database for the Stand Up to Cancer Pediatric Dream team.
3. Computational server for a precision therapy trial to be conducted with the Children's Oncology Group.
4. Computational server for a precision therapy trial to be conducted with the Center for Cancer Research, NCI.
The research goals are to integrate the data, decipher the biology of these cancers and to identify and validate biomarkers and novel therapeutic targets and to rapidly translate findings to the clinic. This new system will host the largest collection of clinically annotated pediatric cancer genomic data ever to be released to the scientific community. Not only will this system enable state-of-the-art precision therapy trials for children and adults with lethal cancers, but also provide clinically annotated high-resolution genomics data for basic science research.
"With the advent of faster, low-cost genome sequencing technology, researchers now have a critical gateway to understanding the underlying molecular pathways for diseases. And for some diseases, every hour closer to discovery and result can mean the difference between life and death," said Walker Stemple, Dell's High Performance Computing Product Manager.
Terascala technology is present in several key areas of the new Dell computer cluster: TeraOS improves the reliability, ease of use, and performance of the Lustre storage in the solution; Terascala gateways enable a direct interface for the genome sequencers to the Lustre storage; and Terascala Support delivers optimized technical support across the entire storage appliance.
"We are very excited to be a contributor to this significant HPC advancement at the NCI," said Steve Butler, CEO of Terascala. "The result is a much faster and more efficient workflow for NCI researchers. Our hope and belief is that NCI researchers will be able to accelerate their work resulting in a faster timeline in breakthroughs in the battle against cancer."
When cancer has spread beyond the site of origin it becomes hard to cure. In addition, children with relapsed or refractory cancers have about a 20 percent chance of survival. Neuroblastoma, a rare cancer that strikes one in 100,000 children annually usually before the age of 5, is so deadly that it is responsible for one in seven pediatric cancer deaths. The cancer comes from the sympathetic nervous system, which controls heart rate, blood pressure and digestion, with aggressive tumors that are unique to each child.
To overcome these challenges, parents and physicians and scientists from the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC; https://nmtrc.org) and TGen have teamed to launch a groundbreaking personalized medicine clinical trial investigation for pediatric cancer. The trial is based on research from a group of collaborating investigators who are developing a personalized medicine process that is intended to permit near "real time" processing of information on patient tumors and prediction of best drugs for a specific patient. This process generates more than 200 billion measurements per patient that must be analyzed, shared and stored.The computation and analysis of this information can take weeks, even months, to process. The Dell solution and TGen software decreased RNA-Seq data analysis time from 7 days to 4 hours.
# # #
Dell Inc. listens to customers and delivers innovative technology and services that give them the power to do more. As one of the leading providers of end-to-end IT solutions for healthcare worldwide, Dell helps healthcare organizations to simplify administration; coordinate and manage patient care; transition from episodic care to prevention and wellness management; and ultimately to deliver personalized medicine. As part of the company's commitment to put technology and expertise to work where it can do the most good for people and the planet, Dell has been working with TGen since 2011 to accelerate pediatric cancer treatment. Learn more at www.dell.com/childrenscancercare or follow @DellHealth on Twitter.
Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. TGen is focused on helping patients with cancer, neurological disorders and diabetes, through cutting edge translational research (the process of rapidly moving research towards patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and rare complex diseases in adults and children. Working with collaborators in the scientific and medical communities literally worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit:www.tgen.org.
TGen Senior Science Writer
About Dr. Javed Khan's laboratory group at NCI
Dr. Khan's laboratory group is one of the largest on the NIH campus applying Next Generation Sequencing (NGS) strategies to investigate cancers. He has leadership roles in national efforts including the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) program, as well as the Stand up to Cancer (SU2C) St. Baldrick's Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers. He and his colleagues in the Genetics Branch are seeking to build a robust, nationally recognized clinical sequencing infrastructure that will support and enable precision therapy trials and to make important scientific discoveries.
NCI Press Officers
Dr. Javed Khan
National Cancer Institute, Bethesda, Md.